SAA、CRP在新型冠状病毒肺炎诊断中的价值

Value of SAA and CRP in diagnosis of patients with COVID-19

目的:探讨血清淀粉样蛋白A(SAA)、C反应蛋白(CRP)在新型冠状病毒肺炎(COVID-19)诊断中的价值。方法:回顾性分析2020年1月~6月本院COVID-19患者的临床资料,包括基本人口学特征、实验室检查结果和影像学检查结果,并与甲流组、疑似组、健康组进行比较分析。结果:COVID-19组患者SAA和CRP明显高于甲流组和疑似组(均P<0.05);COVID-19组SAA和CRP的阳性率显著高于疑似组(均P<0.01),且SAA的阳性率高于CRP;重型和危重型COVID-19患者的年龄、SAA、CRP、IL-6明显高于普通型(均P<0.05)。结论:COVID-19患者中升高的SAA和CRP,可作为COVID-19的早期诊断和辅助诊断的重要参考指标,值得临床进一步推广应用。

Objective:To investigate the diagnostic value of serum amyloid A(SAA)and C-reactlve protein(CRP)in patients with COVID-19.Methods:Clinical data of COVID-19 patients in our hospital between January 2019 andJune 2019 were were retrospectively analyzed,including basic demographic characteristics,laboratory results,and radiographic results,and compared with influenza A patients,suspected patients,healthy people.Results:The levels of SAA and CRP in COVID-19 patients were higher than those in influenza A patients and suspected patients(all P<0.05).The positive rates of SAA and CRP in COVID-19 patients were higher than those in suspected patients(all P<0.05),and the positive rate of SAA was higher than that of CRP.Comparing three types of COVID-19 patients,severe type and critical type had higher levels of age,SAA,CRP and IL-6 than common type(all P<0.05).Conclusion:Increased levels of SAA and CRP in COVID-19 patients,can be an important indicator in early diagnosis and differential diagnosis of COVID-19,and have extensively clinical application value.